|
gptkbp:instanceOf
|
gptkb:biotechnology
|
|
gptkbp:awards
|
gptkb:CII_National_Award_for_Excellence_in_Water_Management
gptkb:Golden_Peacock_Award_for_Risk_Management
|
|
gptkbp:CEO
|
gptkb:Erez_Israeli
|
|
gptkbp:collaboratedWith
|
gptkb:Sputnik_V_(Russian_Direct_Investment_Fund)
|
|
gptkbp:country
|
gptkb:India
|
|
gptkbp:foundedBy
|
gptkb:Kallam_Anji_Reddy
|
|
gptkbp:foundedYear
|
1984
|
|
gptkbp:hasResearchCenter
|
gptkb:India
gptkb:United_Kingdom
gptkb:United_States
|
|
gptkbp:headquartersLocation
|
gptkb:Hyderabad
|
|
gptkbp:industry
|
Pharmaceuticals
|
|
gptkbp:ISIN
|
INE089A01023
|
|
gptkbp:listedOn
|
gptkb:Forbes_Global_2000
gptkb:Nifty_50
|
|
gptkbp:manufacturer
|
COVID-19 drugs
|
|
gptkbp:manufacturingFacilities
|
gptkb:China
gptkb:India
gptkb:Mexico
gptkb:Netherlands
gptkb:United_Kingdom
gptkb:United_States
|
|
gptkbp:numberOfEmployees
|
over 20,000
|
|
gptkbp:operatesIn
|
Global
|
|
gptkbp:parentCompany
|
gptkb:Dr._Reddy's_Holdings_Ltd.
|
|
gptkbp:products
|
Over-the-counter drugs
Active pharmaceutical ingredients
Generic drugs
Biosimilars
|
|
gptkbp:revenue
|
INR 24,500 crore (2023)
|
|
gptkbp:stockExchange
|
gptkb:NYSE
gptkb:NSE
BSE
|
|
gptkbp:stockSymbol
|
gptkb:DRREDDY
|
|
gptkbp:subsidiary
|
gptkb:Dr._Reddy's_Laboratories_SA
|
|
gptkbp:website
|
https://www.drreddys.com/
|
|
gptkbp:bfsParent
|
gptkb:K._Anji_Reddy
|
|
gptkbp:bfsLayer
|
6
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Dr. Reddy's Laboratories
|